Viral vector bioprocessing & analytics: tools and innovations to meet future demand

CELL AND GENE THERAPY INSIGHTS

Viral vector bioprocessing & analytics: tools and innovations to meet future demand

April 2020
Viral vector bioprocessing & analytics: tools and innovations to meet future demand
Download PDF

Expert Insight

Lentiviral vector manufacturing process enhancement utilizing TFDF<sup>™</sup> technology

Lentiviral vector manufacturing process enhancement utilizing TFDF™ technology

T Williams, O Goodyear, L Davies et al.
5 May 2020
Read

Innovator Insight

Development and validation of quantitative real-time PCR for the detection of residual HEK-293 host cell DNA

Development and validation of quantitative real-time PCR for the detection of residual HEK-293 host cell DNA

Kara Norman
29 April 2020
Read
A reproducible, high-throughput platform to quantitatively study AAVs

A reproducible, high-throughput platform to quantitatively study AAVs

James White, Natalia Rodionova
28 April 2020
Read

Interview

Scaling AAV vector manufacture: overcoming roadblocks to the translation of gene therapies

Scaling AAV vector manufacture: overcoming roadblocks to the translation of gene therapies

Nicole Faust
15 May 2020
Read
Vector production in academia: obstacles and opportunities

Vector production in academia: obstacles and opportunities

Daniela Bischof, Emily Hopewell
5 May 2020
Read
Drawing parallels and cross-pollinating ideas between viral vector and vaccine fields

Drawing parallels and cross-pollinating ideas between viral vector and vaccine fields

Amine Kamen
5 May 2020
Read
What is ‘quality’ in viral vector manufacture? Strengths and limitations of current analytical tools

What is ‘quality’ in viral vector manufacture? Strengths and limitations of current analytical tools

Markus Hörer
5 May 2020
Read
How are fixed-bed bioreactors set to change viral vector processing?

How are fixed-bed bioreactors set to change viral vector processing?

Pim Velthof, Pranav Puri, Jolanda Van Vliet
28 April 2020
Read
Are suspension-based systems for cell and gene therapy key to commercial-scale manufacture?

Are suspension-based systems for cell and gene therapy key to commercial-scale manufacture?

Patrick Erbacher
27 April 2020
Read

Webinars

Lentiviral vector process to accelerate cell and gene therapy clinical development and commercialization

Lentiviral vector process to accelerate cell and gene therapy clinical development and commercialization

Kevin Beck
16 April 2020
Watch
Scaling up viral vector manufacturing with adherent and suspension cell cultures

Scaling up viral vector manufacturing with adherent and suspension cell cultures

C Glover, R Legmann, S Gupta
21 April 2020
Watch
Advances in gene therapy delivery: next-generation transfection reagent for large-scale AAV manufacturing

Advances in gene therapy delivery: next-generation transfection reagent for large-scale AAV manufacturing

Mathieu Porte, Malik Hellal
29 April 2020
Watch
Stable AAV producer cell lines: elevating vector manufacturing

Stable AAV producer cell lines: elevating vector manufacturing

Silke Wissing
5 May 2020
Watch
AAV downstream processing for industrial scale production – moving towards commercial manufacturing

AAV downstream processing for industrial scale production – moving towards commercial manufacturing

Orjana Terova, Mikhail Goldfarb
20 May 2020
Watch